Nuvectis Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule drugs for serious diseases. Its pipeline includes kinase inhibitors aimed at advanced solid tumors and a complement Factor B inhibitor for conditions driven by dysregulated complement activity. The company focuses on precision approaches where targeted pathway blockade may address high unmet medical need.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -6.3 | — |
| Q3 2025 | 0 | — | -9.9 | — |
| Q4 2025 | 0 | — | -7.3 | — |
| Q1 2026 | 0 | — | -6 | — |
| Q2 2026 | 0 | — | -7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Mama's Creations, Inc. (MAMA), IBEX Limited (IBEX), MMTec, Inc. (MTC), Avalo Therapeutics, Inc. (AVTX), Matthews International Corporation (MATW), Gilat Satellite Networks Ltd. (GILT)